Influence of Glimepiride on Plasma Concentrations and Antihypertensive Effects of Losartan and Losartan Carboxylic Acid in the Patients with Type 2 Diabetes Mellitus Complicated with Hypertension
- VernacularTitle:格列美脲对2型糖尿病合并高血压患者氯沙坦及氯沙坦羧酸血药浓度与降压效果的影响
- Author:
Qiuju LÜ
1
;
Qianghong PU
;
Yi XIAO
;
Hui LI
;
Dan XU
;
Qin YANG
;
Zhiwen ZHANG
;
Huan LIU
;
Jing FENG
;
Rui XU
;
Jin ZHANG
Author Information
1. 乐山市人民医院 四川乐山614000
- Keywords:
Type 2 diabetes mellitus;
Hypertension;
Glimepiride;
Losartan;
Losartan carboxylic acid;
Plasma drug concentra-tion;
Drug interactions
- From:
China Pharmacist
2018;21(2):276-278
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the influence of glimepiride on the plasma concentrations and antihypertensive effects of losartan and its active metabolite losartan carboxylic acid(E-3174) in the patients with type 2 diabetes mellitus and hypertension. Methods:Pragmatic randomized controlled trial was used in the clinical study. Forty-five patients were enrolled and randomized into glimepiride group and the control group. Losartan was used as the antihypertensive drug in the two groups. After two-week interference,the plasma concentrations of losartan and its active metabolite E-3174 were determined using an LC-MS/MS method and the reduction of hyperten-sion was measured. Results:The plasma trough concentrations of losartan in glimepiride group was not higher than those in the control group,and those of E-3174 in glimepiride group was not lower than those in the control group. Additionally,the reduction of hyperten-sion was similar in the two groups. Conclusion: Glimepiride does not influence the plasma concentrations and the antihypertensive effects of losartan and its active metabolite E-3174 in the patients with type 2 diabetes mellitus and hypertension, suggesting no drug-drug interactions between them. Owing to the small sample,large clinical trial should be performed to confirm the above conclusion.
